Results 41 to 50 of about 11,732 (171)

Multimodal Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma (PDAC) With Vascular Involvement: What Is the Impact of Radiation on Perioperative Outcomes, Local Control, and Survival?

Journal of Surgical Oncology, EarlyView.
ABSTRACT Objectives Neoadjuvant chemoradiation for PDAC with vascular invasion remains understudied. The aim of this study is to compare neoadjuvant chemotherapy with chemoradiation (NAC + CRT) versus neoadjuvant chemotherapy (NAC) for PDAC with vascular involvement.
Dhruv J. Patel, Lauren M. Janczewski, Joseph H. Cotler, George Molina, Brett L. Ecker, David Bentrem, Shishir K. Maithel, Mohamed E. Abazeed, John P. Hayes, Bryan Palis, Amanda B. Francescatti, Ronald J. Weigel, Judy Boughey, Lesly Dossett, Akhil Chawla   +14 more
wiley   +1 more source

The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer

, 2013
International audienceIn 2010, the FOLFIRINOX regimen (bolus and infusional 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) emerged as a new option in patients with metastatic pancreatic cancer and a good performance status.
Gavoille, Céline, Ychou, Marc, Ducreux, Michel, Samalin, Emmanuelle, Conroy, Thierry   +4 more
core   +1 more source

FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules

Therapeutic Advances in Medical Oncology, 2020
Background: Pancreatic adenocarcinoma is the fourth leading cause of cancer-related death. In cases with metastasis, the combination of 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) or gemcitabine-based chemotherapy regimens are considered the
Francesca Foschini, Fabiana Napolitano, Alberto Servetto, Roberta Marciano, Eleonora Mozzillo, Anna Chiara Carratù, Antonio Santaniello, Pietro De Placido, Priscilla Cascetta, Giovanni Butturini, Isabella Frigerio, Paolo Regi, Nicola Silvestris, Sabina Delcuratolo, Enrico Vasile, Caterina Vivaldi, Cataldo Bianco, Sabino De Placido, Luigi Formisano, Roberto Bianco   +19 more
doaj   +1 more source

Integrated Analysis of the RASH Study with the Use of the “Burden of Therapy” (BOTh^®TM) Methodology—A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic Cancer

Current Oncology, 2023
This analysis of the RASH trial (NCT01729481) aimed at gaining a better understanding of the “Burden of Therapy” (BOTh®TM) in pancreatic ductal adenocarcinoma (PDAC).
Klara Dorman, Stefan Boeck, Robert J. Snijder, Jens T. Siveke, Michael Schenk, Julia Mayerle, Karel Caca, Jens Freiberg-Richter, Ludwig Fischer von Weikersthal, Frank Kullmann, Anke Reinacher-Schick, Martin Fuchs, Stephan Kanzler, Volker Kunzmann, Thomas J. Ettrich, Danmei Zhang, Swantje Held, Ayad Abdul-Ahad, Michael von Bergwelt-Baildon, Volker Heinemann, Michael Haas   +20 more
doaj   +1 more source

Chemotherapy After Resection of Pancreatic Ductal Adenocarcinoma: Impact of Different Regimens in a Real‐World Population

Journal of Surgical Oncology, EarlyView.
ABSTRACT Introduction The PRODIGE 24/CCTG PA.6‐ trial has shown an overall survival (OS) up to 55 months in patients treated with (modified) 5‐fluorouracil, leucovorin, irinotecan and oxaliplatin ((m)FOLFIRINOX) chemotherapy after resection of pancreatic ductal adenocarcinoma (PDAC). The applicability of these results to a real‐world patient population
N. C. Biesma, G. A. Cirkel, N. Haj Mohammad, M. Los, R. C. Verdonk, I. Q. Molenaar, L. A. Daamen, H. C. van Santvoort   +7 more
wiley   +1 more source

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

, 2018
International audienceBACKGROUND:Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the
Volet, Julien, Artru, Pascal, Faroux, Roger, Choné, Laurence, Malka, David, Trials Group, Canadian Cancer, Rat, Patrick, Khemissa-Akouz, Faiza, Bouhier-Leporrier, Karine, Biagi, James, Hammel, Pascal, Wei, Alice, Assenat, Eric, Conroy, Thierry, Hebbar, Mohamed, Legoux, Jean-Louis, Group, Unicancer-Gi–prodige, Breysacher, Gilles, Gourgou, Sophie, Ben Abdelghani, Meher, Jouffroy-Zeller, Claire, Juzyna, Beata, Kavan, Petr, Lecomte, Thierry, Francois, Eric, Texereau, Patrick, O'Callaghan, Christopher, Raoul, Jean-Luc, Castan, Florence, Di Fiore, Frédéric, Ychou, Marc, Cripps, Christine, Bachet, Jean-Baptiste, Sauvanet, Alain   +33 more
core   +1 more source

FOLFIRINOX for advanced pancreatic cancer:The Princess Margaret Cancer Centre experience [PDF]

, 2016
Background: FOLFIRINOX has been shown to significantly increase both overall survival (OS) and progression-free survival (PFS) in metastatic pancreas cancer. There is limited data regarding the treatment of locally advanced pancreatic cancer.
Wang, Lisa, Jennifer J Knox, Kazim Giby, Malcolm J Moore, Natalie Cook, Cook, Natalie; id_orcid, Chllamma, Muralidharan K., Hedley, David W., David W Hedley, Giby, Kazim, Anna Dodd, Lisa Wang, Dodd, Anna, Neesha C Dhani, Dhani, Neesha C., Moore, Malcolm J., Knox, Jennifer J., Muralidharan K Chllamma   +17 more
core   +1 more source

Sensing‐Integrated Patient‐Derived Tumorspheres Predict Chemotherapeutic Efficacy via Local Extracellular pH Dynamics

Small, EarlyView.
The study introduces a 3D sensing‐integrated platform enabling real‐time, non‐invasive monitoring of pH dynamics in patient‐derived PDAC tumorspheres. It revealed distinct extracellular acidification patterns under FOLFIRINOX, gemcitabine, and paclitaxel, correlating with therapeutic efficacy.
Stefania Forciniti, Valentina Onesto, Anna Chiara Siciliano, Helena Iuele, Stefano D'Ugo, Norma Depalma, Cinzia Fasano, Alessandro D'Amuri, Giuseppe Gigli, Marcello G. Spampinato, Loretta L. del Mercato   +10 more
wiley   +1 more source

COMBINATION CHEMOTHERAPY REGIMENS IN PANCREATIC CANCER

Медицинский совет, 2017
Pancreatic cancer is characterized by its aggressive behaviour and high metastatic potential, and in most cases the disease is detected in inoperable stages.
A. S. POPOVA, I. A. POKATAEV, S. A. TYULYANDIN,   +2 more
doaj   +1 more source

Cost‐effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab‐paclitaxel in borderline resectable/locally advanced pancreatic cancer patients

Cancer Reports, 2022
Background The 2020 National Comprehensive Cancer Network guidelines recommend neoadjuvant FOLFIRINOX or neoadjuvant gemcitabine plus nab‐paclitaxel (G‐nP) for borderline resectable/locally advanced pancreatic ductal adenocarcinoma (BR/LA PDAC).
Myles A. Ingram, Brianna N. Lauren, Yoanna Pumpalova, Jiheum Park, Francesca Lim, Susan E. Bates, Fay Kastrinos, Gulam A. Manji, Chung Yin Kong, Chin Hur   +9 more
doaj   +1 more source